|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-2-9
|
|
pubmed:abstractText |
The 4-year results of this trial demonstrated that a higher dose of epirubicin with cyclophosphamide (HEC) is superior to a lower dose of epirubicin, 60 mg/m(2) (EC), for event-free survival (EFS; 27% reduction), but is not superior to classical oral cyclophosphamide, methotrexate, and fluorouracil (CMF) in the adjuvant treatment of node-positive breast cancer. Herein we report the 15-year data on efficacy and long-term toxicity of this three-arm Belgian multicenter trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BeauduinMarcM,
pubmed-author:Closon-DejardinMarie ThérèseMT,
pubmed-author:CornezNathalieN,
pubmed-author:DolciStellaS,
pubmed-author:FinetClaudeC,
pubmed-author:FocanChristianC,
pubmed-author:GobertPhilippeP,
pubmed-author:KergerJosephJ,
pubmed-author:NogaretJean MJM,
pubmed-author:PaesmansMarianneM,
pubmed-author:Piccart-GebhartMartine JMJ,
pubmed-author:RiesFernandF,
pubmed-author:TagnonAlainA,
pubmed-author:VindevoghelAnitaA,
pubmed-author:de AzambujaEvandroE,
pubmed-author:di LeoAngeloA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
720-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19103732-Adult,
pubmed-meshheading:19103732-Aged,
pubmed-meshheading:19103732-Antibiotics, Antineoplastic,
pubmed-meshheading:19103732-Antineoplastic Agents, Alkylating,
pubmed-meshheading:19103732-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19103732-Belgium,
pubmed-meshheading:19103732-Breast Neoplasms,
pubmed-meshheading:19103732-Chemotherapy, Adjuvant,
pubmed-meshheading:19103732-Cyclophosphamide,
pubmed-meshheading:19103732-Disease-Free Survival,
pubmed-meshheading:19103732-Epirubicin,
pubmed-meshheading:19103732-Female,
pubmed-meshheading:19103732-Fluorouracil,
pubmed-meshheading:19103732-Humans,
pubmed-meshheading:19103732-Lymph Nodes,
pubmed-meshheading:19103732-Methotrexate,
pubmed-meshheading:19103732-Middle Aged
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
|
|
pubmed:affiliation |
Institut Jules Bordet and Université Libre de Bruxelles, Brussels.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
